Teclistamab produced deep responses in high-risk smouldering multiple myeloma in results from the randomized phase II ImmunoPRISM trial. The bispecific T-cell engager achieved high rates of complete response and measurable residual disease negativity, suggesting meaningful disease control for patients who are typically monitored until progression. The findings add to growing evidence that earlier intervention with T-cell engaging therapies may alter the trajectory of smouldering disease. The randomized design also helps contextualize response magnitude within a controlled study framework. For industry stakeholders, the clinical signal supports continued refinement of risk stratification and treatment timing, particularly as bispecifics compete for positions earlier in the myeloma treatment continuum.